Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
Market Cap$15.91B
Close$
$102.00
24.6% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
24.6% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details$6.99
91.5% downside
Current Fair Value
91.5% downsideOvervalued by 91.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.91 Billion |
|---|---|
| Enterprise Value | $15.95 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $1.07 |
| Beta | 0.55 |
| Outstanding Shares | 189,879,803 |
| Avg 30 Day Volume | 1,906,518 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 77.45 |
|---|---|
| PEG | 104.16 |
| Price to Sales | 6.29 |
| Price to Book Ratio | 3.15 |
| Enterprise Value to Revenue | 6.45 |
| Enterprise Value to EBIT | 90.02 |
| Enterprise Value to Net Income | 77 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
ESG Score
No data
About Biomarin Pharmaceutical Inc.
CEO: Jean-Jacques Bienaime